Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 329

1.

Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance.

Grimaldi-Bensouda L, Rossignol M, Koné-Paut I, Krivitzky A, Lebrun-Frenay C, Clet J, Brassat D, Papeix C, Nicolino M, Benhamou PY, Fain O, Costedoat-Chalumeau N, Courcoux MF, Viallard JF, Godeau B, Papo T, Vermersch P, Bourgault-Villada I, Breart G, Abenhaim L; PGRx-AD Study Group..

J Autoimmun. 2017 Feb 9. pii: S0896-8411(16)30214-1. doi: 10.1016/j.jaut.2017.01.005. [Epub ahead of print]

PMID:
28190705
2.

Myogenic abnormalities in intensive care can hide an uncommon diagnosis.

London F, Benzidi Y, Vermersch P, Tard C.

Acta Neurol Belg. 2017 Feb 7. doi: 10.1007/s13760-017-0756-0. [Epub ahead of print] No abstract available.

PMID:
28176267
3.

Survey of diagnostic and treatment practices for multiple sclerosis in Europe.

Fernández O, Delvecchio M, Edan G, Fredrikson S, Gionvannoni G, Hartung HP, Havrdova E, Kappos L, Pozzilli C, Soerensen PS, Tackenberg B, Vermersch P, Comi G.

Eur J Neurol. 2017 Mar;24(3):516-522. doi: 10.1111/ene.13236.

PMID:
28139062
4.

Continuous hemifacial myokymia as the revealing symptom of demyelinating disease of the CNS.

London F, Hadhoum N, Zéphir H, Vermersch P, Outteryck O.

Mult Scler Relat Disord. 2017 Jan;11:10-11. doi: 10.1016/j.msard.2016.11.001.

PMID:
28104248
5.

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis.

Brochet B, Deloire MS, Perez P, Loock T, Baschet L, Debouverie M, Pittion S, Ouallet JC, Clavelou P, de Sèze J, Collongues N, Vermersch P, Zéphir H, Castelnovo G, Labauge P, Lebrun C, Cohen M, Ruet A; PROMESS study investigators..

PLoS One. 2017 Jan 3;12(1):e0168834. doi: 10.1371/journal.pone.0168834.

6.

Autoimmune cerebellar ataxia with glutamic acid decarboxylase 65 antibodies associated with central vestibular symptoms.

London F, Hadhoum N, Zéphir H, Outteryck O, Vermersch P.

Acta Neurol Belg. 2016 Dec 17. [Epub ahead of print] No abstract available.

PMID:
27988832
7.

Bent spine syndrome as the initial symptom of late-onset Pompe disease.

Taisne N, Desnuelle C, Juntas Morales R, Ferrer Monasterio X, Sacconi S, Duval F, Sole G, Flipo RM, Lacour A, Vermersch P, Cardon T.

Muscle Nerve. 2016 Nov 15. doi: 10.1002/mus.25478. [Epub ahead of print]

PMID:
27862019
8.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Pignolet B, Schwab N, Schneider-Hohendorf T, Bucciarelli F, Biotti D, Averseng-Peaureaux D, Outteryck O, Ongagna JC, de Sèze J, Brochet B, Ouallet JC, Debouverie M, Pittion S, Defer G, Derache N, Hautecoeur P, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Berger E, Pelletier J, Rico A, Zéphir H, Laplaud D, Wiertlewski S, Camu W, Thouvenot E, Casez O, Moreau T, Fromont A, Vukusic S, Papeix C, Vermersch P, Comabella M, Lebrun-Frenay C, Wiendl H, Brassat D; BIONAT, SFSEP, and BEST-MS networks..

Neurology. 2016 Dec 6;87(23):2491-2494. No abstract available.

PMID:
27815407
9.

JCV serology in time: 3 years of follow-up.

Cambron M, Hadhoum N, Duhin E, Lacour A, Chouraki A, Vermersch P.

Acta Neurol Scand. 2016 Oct 20. doi: 10.1111/ane.12699. [Epub ahead of print]

PMID:
27766611
10.
11.

Isaacs' syndrome and Hodgkin lymphoma: a rare association.

London F, Bancilhon JB, Tard C, Vermersch P, Hadhoum N.

Acta Neurol Belg. 2016 Aug 10. [Epub ahead of print] No abstract available.

PMID:
27509879
12.

Conclusions: Calls to action for improving the life of MS patients and their families.

Vermersch P, Smets L, Gold R.

Mult Scler. 2016 Aug;22(2 Suppl):71-7. doi: 10.1177/1352458516650738.

PMID:
27465617
13.

The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?

Vermersch P, Berger T, Gold R, Lukas C, Rovira A, Meesen B, Chard D, Comabella M, Palace J, Trojano M.

Mult Scler. 2016 Aug;22(2 Suppl):18-33. doi: 10.1177/1352458516650739.

PMID:
27465613
14.

The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?

Vermersch P, Faller A, Czarnota-Szałkowska D, Meesen B, Thalheim C.

Mult Scler. 2016 Aug;22(2 Suppl):9-17. doi: 10.1177/1352458516650742.

PMID:
27465612
15.

Introduction: Do we need multi-stakeholder colloquia in MS?

Vermersch P, Smets L, Gold R.

Mult Scler. 2016 Aug;22(2 Suppl):4-8. doi: 10.1177/1352458516650740.

PMID:
27465611
16.

Late-onset of Alpers-Huttenlocher syndrome: an unusual cause of refractory epilepsy and liver failure.

London F, Hadhoum N, Outteryck O, Vermersch P, Zéphir H.

Acta Neurol Belg. 2016 Jul 15. [Epub ahead of print] No abstract available.

PMID:
27422324
17.

Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?

Vermersch P, Hobart J, Dive-Pouletty C, Bozzi S, Hass S, Coyle PK.

Mult Scler. 2016 Jun 30. pii: 1352458516657441. [Epub ahead of print]

PMID:
27364322
18.

Impact of multiple sclerosis on employment and use of job-retention strategies: The situation in France in 2015.

Fantoni-Quinton S, Kwiatkowski A, Vermersch P, Roux B, Hautecoeur P, Leroyer A.

J Rehabil Med. 2016 Jun 13;48(6):535-40. doi: 10.2340/16501977-2093.

19.

Altered signal intensity of active enhancing inflammatory lesions using post-contrast double inversion recovery MR sequence.

Hodel J, Badr S, Outteryck O, Lebert P, Chechin D, Benadjaoud MA, Pruvo JP, Vermersch P, Leclerc X.

Eur Radiol. 2017 Feb;27(2):637-641. doi: 10.1007/s00330-016-4416-1.

PMID:
27229340
20.

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.

Otero-Romero S, Sastre-Garriga J, Comi G, Hartung HP, Soelberg Sørensen P, Thompson AJ, Vermersch P, Gold R, Montalban X.

Mult Scler. 2016 Oct;22(11):1386-1396. Review.

PMID:
27207462
Items per page

Supplemental Content

Loading ...
Support Center